Provided by Tiger Fintech (Singapore) Pte. Ltd.

Passage Bio, Inc.

0.3490
-0.0087-2.43%
Volume:91.15K
Turnover:31.35K
Market Cap:21.69M
PE:-0.33
High:0.3600
Open:0.3600
Low:0.3323
Close:0.3577
Loading ...

BRIEF-Passage Bio Inc On Jan 8, Board Approved, And Management Began Implementing, Restructuring Plan

Reuters
·
10 Jan

Passage Bio Inc: to Cease Its Lab Operations at Its Approximately 62,000 Feet of Leased Laboratory Space in Hopewell, New Jersey

THOMSON REUTERS
·
10 Jan

Passage Bio : to Reduce Operating Costs and Better Align Its Workforce With Needs of Its Strategic Research and Development Strategy

THOMSON REUTERS
·
10 Jan

Passage Bio Inc: Pursuing Opportunities to Sublease Space at Laboratory Lease to Offset Portions of Its Financial Obligations

THOMSON REUTERS
·
10 Jan

Passage Bio Inc: on Jan 8, Board Approved, and Management Began Implementing, Restructuring Plan

THOMSON REUTERS
·
10 Jan

Passage Bio Inc: Expects Restructuring Plan Will Decrease Its Annual Operating Costs by About $9.0 Mln to $11.0 Mln

THOMSON REUTERS
·
10 Jan

Passage Bio Inc: Under Restructuring Plan, Company Is Reducing Its Overall Workforce by About 55%

THOMSON REUTERS
·
10 Jan

Passage Bio Announces Interim Data From Uplift-D Study in Ftd-Grn and Provides Business Updates

THOMSON REUTERS
·
10 Jan

Passage Bio Inc - Expect to Report 12-Month Data From Dose 1 in 2H 2025

THOMSON REUTERS
·
10 Jan

Passage Bio Inc - on Track to Initiate Dosing of Ftd-C9orf72 Patients in 1H 2025

THOMSON REUTERS
·
10 Jan

Passage Bio Inc - Extended Cash Runway Into 1Q 2027 by Reducing Operating Expenses

THOMSON REUTERS
·
10 Jan

Passage Bio Inc - Pbft02 Shows Durable Csf Pgrn Levels and Reduced Plasma Nfl Levels

THOMSON REUTERS
·
10 Jan

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Simply Wall St.
·
07 Jan

Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Simply Wall St.
·
29 Dec 2024

Passage Bio Coverage Assumed by Wedbush at Outperform

Dow Jones
·
29 Nov 2024

Passage Bio Shares up 25% at 83 Cents After Wedbush Assumes Coverage With Outperform Rating

THOMSON REUTERS
·
29 Nov 2024

BUZZ-Passage Bio gains as Wedbush assumes coverage with 'outperform' rating

Reuters
·
29 Nov 2024

Passage Bio assumed with an Outperform at Wedbush

TIPRANKS
·
29 Nov 2024

Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating

MT Newswires Live
·
29 Nov 2024

Passage Bio Is Maintained at Buy by Chardan Capital

Dow Jones
·
15 Nov 2024